With the intensified transformation of the pharmaceutical industry, pharmaceutical companies' innovation investment is constantly hitting new highs

Entering October, the transcripts of listed companies in the first three quarters of 2021 have entered a period of intensive disclosure
.
From the current point of view, many pharmaceutical companies have generally improved their performance, and their research and development expenses have also started to soar, and have created new highs
.
Among them, Hengrui Medicine is the representative of this status quo
.
Recently, Hengrui Pharmaceuticals announced its operating results for the third quarter of 2021, showing that Hengrui Pharmaceuticals achieved operating income of 20.
199 billion yuan in the first three quarters of this year, a year-on-year increase of 4.
05%
.
Although revenue growth has slowed, investment in innovation has increased substantially
.
In 2021, the company will further increase its investment in innovation.
In the first three quarters, it has invested a total of 4.
142 billion yuan in research and development, an increase of 23.
9% year-on-year, and accounting for 20.
5% of operating income
.
The analysis believes that with the internal reform of the pharmaceutical industry and the intensification of international competition, pharmaceutical companies generally face greater challenges
.
Affected by this, Hengrui, as a representative enterprise of China's pharmaceutical innovation, is also accelerating adjustment and transformation through innovation
.
Affected by this, it is conceivable that R&D expenses have risen sharply
.
At present, from the perspective of disclosed information, Hengrui's pipeline of innovative drug R&D pipelines is already abundant
.
In the first half of 2021, the number of NDA approvals has reached as high as 5, which is close to the number of approvals for the whole year of 2020
.
It is worth mentioning that Hengrui Medicine's many potential blockbuster products are gaining momentum.
With the continuous enhancement of the core competitiveness of the moat, Hengrui Medicine's future will be very worth looking forward to
.
It is worth mentioning that BeiGene expects to release its financial results for the three and nine months ending September 30, 2021 after the US stock market is closed on November 4, 2021 (Thursday)
.
The industry believes that from the first half of 2021, its R&D expenditure has reached 677 million US dollars (about 4.
38 billion yuan), and the R&D expenditure in the first three quarters will also reach a new high..
In addition, Zai Lab's R&D investment in the first half of the year has also approached Hengrui's, reaching 2.
24 billion yuan, an increase of 239.
1% over the same period last year, accounting for 606.
7% of revenue.
Following this trend, the industry expects its report in the third quarter in the future.
The internal R&D expenditure will also be considerable
.
In addition to domestic pharmaceutical companies, in fact, the level of R&D investment of multinational pharmaceutical companies is also rising
.
It is reported that in the first half of 2021, Roche, Merck, Johnson & Johnson, and Bristol-Myers Squibb all spent more than US$5 billion in research and development
.
Among them, Roche's research and development expenses in the first half of the year reached 7.
75 billion US dollars, accounting for 22.
86% of revenue, which shows that the company is optimistic about the research and development of new drugs
.
In general, with the accelerated development of the innovative drug industry at home and abroad, the enthusiasm of pharmaceutical companies for the development and introduction of new drugs continues to rise
.
In the future, under a series of policies to promote the development of innovative drugs, the pharmaceutical industry will continue to invest in research and development
.
In fact, many domestic pharmaceutical companies have made it clear that they will continue to increase their investment in innovative drugs
.
For example, Enhua Pharmaceuticals said that the company will continue to steadily promote the research and development of innovative drugs and high-barrier generic drugs, and mentioned that the company will also invest a large amount of funds for drug R&D and innovation every year based on future development needs.
Sexual evaluation
.